A cost-of-illness study of Behcet syndrome in Italy

被引:2
作者
Lorenzoni, Valentina [1 ]
Marinello, Diana [2 ]
Palla, Ilaria [1 ]
Mosca, Marta [2 ]
Turchetti, Giuseppe [1 ]
Talarico, Rosaria [2 ]
机构
[1] Scuola Super Sant Anna, Inst Management, Piazza Martiri Liberta 33, I-56127 Pisa, Italy
[2] Univ Pisa, Rheumatol Unit, Azienda Osped Univ Pisana, Pisa, Italy
关键词
Behcet; Cost-of-illness; Economic; RARE DISEASES; ORPHAN DRUGS; LIFE;
D O I
10.1007/s10198-023-01593-8
中图分类号
F [经济];
学科分类号
02 ;
摘要
ObjectiveThis study aims at evaluating the cost-of-illness (COI) of patients diagnosed with Behcet's syndrome (BS) in Italy, trying to depict the impact of different costs' components to the overall economic burden and analysing the variability of costs according to years since diagnosis and age at first symptoms.MethodsWith a cross-sectional evaluation, we surveyed a large sample of BS patients in Italy assessing several dimensions related to BS, also including fact related to the use of health resources utilization, formal and informal care, and productivity losses. Overall costs, direct health, direct non-health, and indirect costs were thus estimated per patient/year considering a Societal perspective and the impact of years since diagnosis, age at first symptoms on costs was evaluated using generalized linear model (GLM) and a two-part model, adjusting for age and distinguishing among employed and non-employed responders.ResultsA total of 207 patients were considered in the present study. From the perspective of the Society, mean overall costs for BS patient were estimated to be 21,624 euro (0;193,617) per patient/year. Direct non-health expenses were the main costs component accounting for 58% of the overall costs, followed direct health costs, 36%, while indirect costs because of productivity losses represented 6% of the overall costs. Being employed resulted in significantly lower overall costs (p = 0.006). Results from the multivariate regression analyses suggested that the probability of incurring in overall costs equal to zero decreased as time from BS diagnosis is 1 year or more as compared to newly diagnosed patients (p < 0.001); while among those incurring in expenses, costs decreased for those experiencing first symptoms between 21 and 30 years (p = 0.027) or later (p = 0.032) as compared to those having symptoms earlier. Similar findings emerged among the subgroups of patients declaring themselves as workers, while no impact of years since diagnosis or age of first symptoms was found among non-workers.ConclusionsThe present study offers a comprehensive overview of the economic consequences imposed by BS in a societal perspective, providing insights into the distribution of the different costs component related to BS, thus helping the development of targeted policies.
引用
收藏
页码:411 / 422
页数:12
相关论文
共 28 条
[1]  
Agenzia Italiana del Farmaco, About us
[2]   Socio-economic burden of rare diseases: A systematic review of cost of illness evidence [J].
Angelis, Aris ;
Tordrup, David ;
Kanavos, Panos .
HEALTH POLICY, 2015, 119 (07) :964-979
[3]  
[Anonymous], EL FARM A
[4]   Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis [J].
Aranda-Reneo, Isaac ;
Rodriguez-Sanchez, Beatriz ;
Pena-Longobardo, Luz Maria ;
Oliva-Moreno, Juan ;
Lopez-Bastida, Julio .
VALUE IN HEALTH, 2021, 24 (03) :431-442
[5]   An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogethERN ReCONNET [J].
Bandeira, Matilde ;
Di Cianni, Federica ;
Marinello, Diana ;
Arnaud, Laurent ;
Cannizzo, Sara ;
Carta, Claudio ;
Cornet, Alain ;
Barril, Sara M. ;
Bulina, Inita ;
Ferraris, Alessandro ;
Fonseca, Joao ;
Gaglioti, Andrea ;
Limper, Marteen ;
Lorenzoni, Valentina ;
Majnik, Judith ;
Matucci-Cerinic, Marco ;
Palla, Ilaria ;
Rednic, Simona ;
Schneider, Matthias ;
Smith, Vanessa ;
Sulli, Alberto ;
Sondergaard, Klaus ;
Ticciati, Simone ;
Tincani, Angela ;
Turchetti, Giuseppe ;
Talarico, Rosaria ;
Cutolo, Maurizio ;
Mosca, Marta ;
Taruscio, Domenica .
FRONTIERS IN MEDICINE, 2022, 9
[6]  
behcet, HOM PORT INF MAL E O
[7]   Valuing the "Burden" and Impact of Rare Diseases: A Scoping Review [J].
Delaye, Julien ;
Cacciatore, Pasquale ;
Kole, Anna .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[8]   Orphan drugs policies: a suitable case for treatment [J].
Drummond, Michael ;
Towse, Adrian .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04) :335-340
[9]  
ec.europa, COMM EUR SIT WEB UFF
[10]   Cost-of-illness studies in rare diseases: a scoping review [J].
Garcia-Perez, Lidia ;
Linertova, Renata ;
Valcarcel-Nazco, Cristina ;
Posada, Manuel ;
Gorostiza, Inigo ;
Serrano-Aguilar, Pedro .
ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)